Apnimed Inc. (APMD)
The price, the headline numbers and the latest news, in one place.
Apnimed Inc. (APMD) Stock Price, Analysis & Data
| Bid | 31.14 |
| Market Cap | 1.09B |
| Revenue (ttm) | 120.15M |
| Net Income (ttm) | 39M |
| n/a | |
| 3.73 | |
| 7.34 | |
| -19.69 | |
| P/B (ttm) | -0.51 |
| P/S (ttm) | 9.07 |
| Earnings Date | n/a |
| Ask | 32.26 |
| Volume | 480,426 |
| Avg. Volume (20D) | 561,241 |
| Open | 26.60 |
| Previous Close | 25.63 |
| Day's Range | 26.01 - 29.56 |
| 52-Week Range | 16.12 - 35.29 |
| Analyst | n/a |
| Price Target | 50.5 (84.51%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About APMD
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts....
Financial Performance
In 2025, Apnimed's revenue was 38.47M, an increase of 380.12% compared to the previous year's 8.01M. Earnings were -932K, a decrease of -99.16%.
Financial StatementsAnalyst Forecast
According to 2 analyst ratings, the average rating for APMD stock is "null". The 12-month stock price forecast is 50.5, which is upside of 84.51% from the latest price.
Stock Forecasts
